Consistency, completeness and external validity of ethnicity recording in NHS primary care records: a cohort study in 25 million patients’ records at source using OpenSAFELY DOI Creative Commons
Colm Andrews, Rohini Mathur, Jon Massey

et al.

BMC Medicine, Journal Year: 2024, Volume and Issue: 22(1)

Published: July 10, 2024

Abstract Background Ethnicity is known to be an important correlate of health outcomes, particularly during the COVID-19 pandemic, where some ethnic groups were shown at higher risk infection and adverse outcomes. The recording patients’ in primary care can support research efforts achieve equity service provision outcomes; however, coding ethnicity present complex challenges. We therefore set out describe detail with a view supporting use this data wide range settings, as part wider robustly define methods using administrative data. Methods completeness consistency OpenSAFELY-TPP database, containing linked hospital records > 25 million patients England. also compared breakdown that 2021 UK census. Results 78.2% registered on 1 January 2022 had their recorded records, rising 92.5% when supplemented was for women than men. rate ranged from 77% South East England 82.2% West Midlands. rates chronic or other serious conditions. For each five broad groups, within 2.9 percentage points population Census whole. multiple 98.7% latest ethnicities matched most frequently coded ethnicity. Patients whose categorised Other likely have discordant (32.2%). Conclusions Primary OpenSAFELY over three quarters all patients, combined sources high level completeness. overall distribution across English practices similar Census, regional variation. This report identifies best available codelist electronic record

Language: Английский

Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021 DOI
Austin E Schumacher, Hmwe Hmwe Kyu, Amirali Aali

et al.

The Lancet, Journal Year: 2024, Volume and Issue: 403(10440), P. 1989 - 2056

Published: March 11, 2024

Language: Английский

Citations

304
Travel vaccines—priorities determined by incidence and impact DOI
Robert Steffen, Lin H. Chen, Peter A. Leggat

et al.

Journal of Travel Medicine, Journal Year: 2023, Volume and Issue: 30(7)

Published: June 19, 2023

Infectious disease epidemiology is continuously shifting. While travel has been disrupted by the COVID-19 pandemic and travel-related epidemiological research experienced a pause, further shifts in vaccine-preventable diseases (VPDs) relevant for travellers have occurred.

Language: Английский

Citations

31
COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history DOI Creative Commons
Hermaleigh Townsley, Joshua Gahir, Timothy Russell

et al.

PLoS ONE, Journal Year: 2024, Volume and Issue: 19(3), P. e0294897 - e0294897

Published: March 21, 2024

Background SARS-CoV-2 variant Omicron rapidly evolved over 2022, causing three waves of infection due to sub-variants BA.1, BA.2 and BA.4/5. We sought characterise symptoms viral loads the course COVID-19 with these in otherwise-healthy, vaccinated, non-hospitalised adults, compared data infections preceding Delta concern (VOC). Methods In a prospective, observational cohort study, healthy vaccinated UK adults who reported positive polymerase chain reaction (PCR) or lateral flow test, self-swabbed on alternate weekdays until day 10. participant-reported load trajectories between caused by VOCs (sub-variants BA.4/5), tested for relationships vaccine dose, PCR cycle threshold (Ct) as proxy using Chi-squared (χ2) Wilcoxon tests. Results 563 episodes were among 491 participants. Across episodes, there was little variation symptom burden (4 [IQR 3–5] symptoms) duration (8 6–11] days). Whilst profiles differed sub-variants, similar sub-variants. Anosmia more frequently after 2 doses sub-variant 3 doses, example: 42% (25/60) participants 9% (6/67) BA.4/5 (χ P < 0.001; OR 7.3 [95% CI 2.7–19.4]). Fever less common (20/60 participants; 33%) than (39/67; 58%; χ = 0.008; 0.4 [CI 0.2–0.7]). Amongst an coryza, fatigue, cough myalgia predominated. Viral peaks did not differ Delta, Omicron, irrespective severity (including asymptomatic participants), VOC vaccination status. Ct values negatively associated time since infected BA.1 (β -0.05 (CI -0.10–0.01); 0.031); however, this trend observed infections. Conclusion Our study emphasises both changing profile era, ongoing transmission risk adults. Trial registration NCT04750356 .

Language: Английский

Citations

8
Impact of SARS-CoV-2 spike antibody positivity on infection and hospitalisation rates in immunosuppressed populations during the omicron period: the MELODY study DOI Creative Commons

Lisa Mumford,

Rachel Hogg, Adam J. Taylor

et al.

The Lancet, Journal Year: 2025, Volume and Issue: 405(10475), P. 314 - 328

Published: Jan. 1, 2025

Language: Английский

Citations

1
Immunocompromised individuals remain at risk of COVID-19: 2023 results from the observational INFORM study DOI Creative Commons
Jennifer K Quint, Sabada Dube,

Lucy Carty

et al.

Journal of Infection, Journal Year: 2025, Volume and Issue: 90(3), P. 106432 - 106432

Published: Jan. 31, 2025

Language: Английский

Citations

1
Comparative effectiveness of two- and three-dose COVID-19 vaccination schedules involving AZD1222 and BNT162b2 in people with kidney disease: a linked OpenSAFELY and UK Renal Registry cohort study DOI Creative Commons
Edward P K Parker, Elsie Horne, William Hulme

et al.

The Lancet Regional Health - Europe, Journal Year: 2023, Volume and Issue: 30, P. 100636 - 100636

Published: May 3, 2023

Kidney disease is a key risk factor for COVID-19-related mortality and suboptimal vaccine response. Optimising vaccination strategies essential to reduce the burden in this vulnerable population. We therefore compared effectiveness of two- three-dose schedules involving AZD1222 (AZ; ChAdOx1-S) BNT162b2 (BNT) among people with kidney England.

Language: Английский

Citations

14
Clinical implications of COVID-19 in chronic kidney disease and end-stage kidney disease DOI
Paul Cockwell, Matthew D. Griffin

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 543 - 568

Published: Jan. 1, 2025

Language: Английский

Citations

0
Reduction in COVID-19-related mortality over time but disparities across population subgroups DOI Creative Commons
Mark W. Tenforde, Ruth Link‐Gelles

The Lancet Public Health, Journal Year: 2023, Volume and Issue: 8(5), P. e327 - e328

Published: April 27, 2023

Language: Английский

Citations

11
Risk factors for all-cause mortality during the COVID-19 pandemic compared with the pre-pandemic period in an adult population of Arkhangelsk, Russia DOI Creative Commons
E. A. Kriеger, Alexander V. Kudryavtsev, Ekaterina Sharashova

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Jan. 7, 2025

Abstract We investigated and compared mortality rates risk factors for pre-pandemic pandemic all-cause in a population-based cohort of men women Arkhangelsk, Russia. A prospective study enrolled 2,324 participants aged 35 to 69 years between 2015 2017. All were followed up deaths using the registry. Mortality per 1000 person-years calculated periods. Cox regression models used investigate demographic, lifestyle, health characteristics associated with increased death both During pandemic, age-standardized women, but minor change was observed men. Older age, smoking, diabetes higher periods sexes. In during obesity, angina, elevated cystatin C levels, history COVID-19. men, asthma hs-Troponin T levels while hs-CRP NT-proBNP Targeted preventive interventions specific can be implemented potential future infectious disease outbreaks.

Language: Английский

Citations

0
Clinical Outcomes of Hospitalized Immunocompromised Patients With COVID-19 and the Impact of Hyperinflammation: A Retrospective Cohort Study DOI Creative Commons
Xinxin Zhang,

Han Xiao-bo,

Chenglong Li

et al.

Journal of Inflammation Research, Journal Year: 2025, Volume and Issue: Volume 18, P. 3385 - 3397

Published: March 1, 2025

Purpose: Immunocompromised patients are at increased risk for severe outcomes from COVID-19 due to their altered immune responses, yet inflammatory profiles and the interplay between immunosuppression remain poorly understood. We aimed illustrate inflammation profile clinical of hospitalized immunocompromised with COVID-19. Methods: conducted a retrospective study using multicenter database included adult Corona virus disease 2019 (COVID-19) in China's late 2022 wave. Crude adjusted 28- 60-day mortality was compared two groups. Inflammatory phenotypes were evaluated by serum interleukin-6 (IL-6) C-reactive protein (CRP) level. The overt analyzed. Results: Among 4078 patients, 348 (8.5%) immunocompromised. had lower crude but higher 28-day (hazard ratio [HR] = 1.55; 95% CI 1.08 2.23) (HR 1.47; 1.05 2.06). Besides, developing hyperinflammation (odd [OR] =1.92; 1.47 2.50, p < 0.001). Moreover, mediated major part deleterious survival effect on Conclusion: Immunodeficiency not only increases short-term also predisposes hyperinflammation. complex immunosuppression, hyperinflammation, warrants more detailed profiling immunity this population. Keywords: COVID-19, in-hospital mortality,

Language: Английский

Citations

0